Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: synchro who wrote (208)	3/14/1998 11:22:00 PM
From: Barron Von Hymen	Read Replies (1) \| Respond to of 656

Could you provide the article to me so I can peruse it? What do you mean by off - as in Hoestsch drug is slower in development that IMNX's? I will do some investigation and get back to you on this.

To: synchro who wrote (208)	3/15/1998 2:04:00 AM
From: targetedmoab	Respond to of 656

I really dont understand Abelson. Hoerscts drug is pretty much like methyltrexate from the little I have seen. TNF receptor is a totally new entity that works by blocking TNF and what causes inflamation. They said Enbrel is not better than methyltrexate.....The recent data proves that wrong, that patients taking methyl. did much better when given Enbrel. If Hoerchts drug is close to approval and so good, why is there hardly any information on it? We have been hearing things from Immunex for over a year....Thing that make you go...HMMMM?????